Antibody-Drug Conjugates 2014 - A Business, Technology & Pipeline Analysis

Jan 29, 2014, 16:00 ET from Research and Markets

DUBLIN, January 29, 2014 /PRNewswire/ --

Research and Markets ( has announced the addition of the "Antibody-Drug Conjugates 2014 - a Business, Technology & Pipeline Analysis" report to their offering. 

     (Logo: )

The report entitled 'Antibody-Drug Conjugates 2014 - A Business, Technology & Pipeline Analysis' is based on the evaluation of more than 90 companies. The report analyzes established and new antibody-drug conjugate (ADC) technologies, business activities and opportunities and assesses more than 100 ADC development and research programs. The commercial value of ADC technologies, ADC products and ADC product candidates is described and valued by means of sales, product prices, company market capitalization, initial public offerings, venture capital and private equity financing, infrastructure investments and financial deal terms. Business deal activities in form of acquisitions, licensing and collaboration agreements and joint ventures between pharma, biotech and the service industry serve to identify those technologies of interest for stakeholders in the ADC industry.

The report was built from the bottom-up by first elaborating Company Profiles from information retrieved from proprietary antibody-drug conjugate database, scientific literature and abstracts, company press releases, company presentations, financial disclosures, clinical trials databases and company websites. A structured analysis was performed for the ADC pipeline, for stakeholders of the ADC industry, for state-of-the art and emerging ADC technologies, for the ADC manufacturing and service industry, and business activities. The report identifies trends for those ADC technologies (target, antibody, drug, linker and conjugation systems) which are of interest for the industry.

The report includes in the Addendum a tabulated Competitor Analysis and lists all relevant business transactions of the last two to three years.

Key Topics Covered:

1 Executive Summary

2 Introduction and Overview of the Report

3 Antibody-Drug Conjugates: Pipeline Description and Analysis

3.1 ADC Pipeline overview and definitions
3.2 Targeting moieties in ADCs and Immunoconjugates
3.3 Drugs & linkers in ADCs and Immunoconjugates
3.4 Targets in ADCs and indications
3.5 Companies clinically developing ADCs
3.6 Clinical success and attrition rates of ADCs

4 Stakeholders in Antibody-Drug Conjugates and Immunoconjugates
4.1 Development companies
4.2 Technology companies
4.3 Manufacturing companies

5 ADC Technologies
5.1 Targets for ADC
5.2 Antibodies for ADCs
5.3 Linkers and conjugation strategies
5.4 Drugs as payload

6 Business with Antibody-Drug Conjugates
6.1 Commercial valuation of ADC technologies and products
6.2 Business opportunities with antibody-drug conjugates

7 ADC & Immunoconjugate Company Profiles
7.1 Development Companies
7.2 Technology Companies
7.3 Contract Manufacturing Companies

8 References

9 Tables

Companies Mentioned:

  • Abbott Contract Manufacturing
  • BSP Pharmaceuticals
  • Carbogen Amcis
  • Daiichi Sankyo
  • Eli Lilly
  • Fujifilm Diosynth Biotechnologies
  • Genmab
  • GlaxoSmithKline
  • Glykos
  • Goodwin Biotechnology
  • Helix Biopharma
  • Heraeus
  • Igenica
  • Lonza
  • Macrogenics
  • Novasep
  • Oncomatrix
  • Oxford BioTherapeutics
  • Pfizer
  • Quanta Biodesign
  • Redwood Biodesign
  • Roche
  • Sanofi
  • TUBE Pharma
  • Takeda Pharmaceutical
  • The Chemistry Research Solution
  • University of California San Diego
  • Wilex (Heidelberg Pharma)
  • WuXi PharmaTech
  • Zhejiang Medicine
  • Zymeworks

For more information visit

Media Contact: Laura Wood, +353-1-481-1716,

SOURCE Research and Markets